State of the Company, new users and innovations in products at PDS continue on excellent track.
Mount Arlington, NJ (PRWEB) May 7, 2009 -- PDS Pathology Data Systems, Ltd., developers of the integrated software systems ToxData®, ReproData®, and PathData®, recently held their annual global user group meeting at the Hanover Marriott in Whippany, New Jersey that was attended by almost 100 users from around the world. The meeting was highlighted by User presentations including Bristol-Myers Squibb, BASF, Pfizer, HSRL, and Merial Ltd.
During a recap of the healthy state of the company, Reto Aerni, CEO of PDS, noted that while traditional licensing of the software strongly continues, there is a growing segment of the users that are licensing the PDS software systems using the company's subscription option-- also known as Software as a Service (SaaS). Unlike other preclinical software vendors, PDS is able to provide subscription access to its software through its GLP-Certified hosting center, thus allowing its customers to preserve fiscal and human resources, reduce implementation time and transfer much of the responsibility of maintaining a GLP-Certified system directly to PDS. As the preclinical market innovator in offering its software via subscription and the only one to be able to do so under a GLP-Certification, PDS customers are able to have confidence regarding the studies conducted using PDS software. It was noted that the subscription option minimizes up-front costs and allows the customers to simply pay-as-they-go without the need of capital expenditures or long-term commitments.
New enhancements to ToxData, the PDS cutting-edge general toxicology and clinical pathology software, reinforced the fact that ToxData is very flexible and easy to use. Unlike most software, ToxData is truly a closed system specifically designed by scientists to increase efficiencies and reduce time to the finished report in a GLP environment, just like the rest of the PDS products.
PDS also demonstrated the major new release of PathData, "Version X," the integrated pathology portion of the product suite. This major release incorporates ultra-modern architecture and beyond-the-horizon features for preclinical pathology.
A featured presentation by Aperio regarding the future of preclinical whole slide digital imaging underscored the PDS commitment to maintaining its innovative lead in areas of vital importance to its customers. Aperio and PDS are working together of the purpose of creating an interface between the two market leaders in whole slide digital imaging and preclinical pathology software. The interface will greatly reduce the time it takes to complete the histopathology portion of studies and significantly boost efficiencies not only for pharmaceuticals, but for CROs and universities as well.
Another presentation by Datamars outlined the usage and future of transponder chips in preclinical studies. In addition, various workshops by functional areas of interest provided the users not only with opportunities to gain focused and in-depth understandings of how to most efficiently utilize the software, but to also network with other users and gain perspectives on how the software is used successfully to meet the widely varied needs of the different users.
All the new PDS customers that have joined since the last user group meeting were introduced. A white paper by PDS staff presented latest FDA regulations and GLP standards, including the SEND initiative, bringing the users up to date with PDS' continuing compliance with the latest requirements.
About the company: PDS is a leading provider of preclinical software systems worldwide. PDS software is used by 8 of the Top 10 pharmaceutical companies around the world as well as well-respected CROs, Pharma, Chemical Companies, and Regulatory Agencies. With headquarters in Basel, Switzerland and North America Operations in Northern New Jersey, PDS develops, distributes and supports its preclinical software products and services through it's own team of science-based professionals that truly understand the needs of their customers.
With reputation of innovation within the preclinical market space, PDS has brought break-through products and features to the scientific community it serves for almost 30 years. The ToxData®, ReproData® and PathData® Systems are modular, scalable, integrated and available through a variety of licensing methods designed to best meet the needs of the customer.
For more information, contact:
Arthur C. Karakos, Senior Vice President, Global Marketing
PDS Preclinical Data Systems, Inc.
North America Marketing Office and User Training Center
100 Stierli Ct, Ste 105
Mount Arlington, NJ 07856 USA
Tel 973 398-2800
Read the full story at http://www.prweb.com/releases/preclinical/software/prweb2382004.htm.
Copyright©2009 Vocus, Inc.
All rights reserved